Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Molecules › Exenatide

Exenatide

GLP-1 · s.c. · AstraZeneca

Data cut 12 November 2026 · page built 16 November 2026 · 0 trial arms · 1 trials with results · 1 registered trials · see on the pipeline board

Summary

Also known as
Bydureon / Byetta
Mechanism
GLP-1
Route
s.c.
Company
AstraZeneca
Highest development stage
—
Status (as of data cut)
Approved (T2D) verify
Next milestone
—

Trial arms: weight, HbA1c and tolerability

No trial arms with extracted efficacy or tolerability data yet.

Outcome trials

Cardiovascular and kidney outcome trials

EXSCEL exenatide QW 2 mg vs placebo · T2D, broad CV risk · n = 14752 · 2017 verified

EndpointHR95 % CIEvents, drug vs controlStatus
3-point MACE primary
First occurrence of CV death, nonfatal MI, or nonfatal stroke
0.910.83–1.00839 vs 905verified
Cardiovascular death
Death from cardiovascular causes (includes death from unknown cause)
0.880.76–1.02340 vs 383verified
All-cause death
Death from any cause
0.860.77–0.97507 vs 584verified
Myocardial infarction
Fatal or nonfatal myocardial infarction
0.970.85–1.10483 vs 493verified
Stroke
Fatal or nonfatal stroke
0.850.70–1.03187 vs 218verified
Hospitalisation for heart failure
Hospitalization for heart failure
0.940.78–1.13219 vs 231verified
Coronary revascularisation
Cardiovascular or peripheral revascularization procedures (NOTE: includes peripheral, not coronary-only)
0.940.85–1.05—verified
Verbatim quotes (7)
  • 3-point MACE · Results, Primary and Secondary Cardiovascular Outcomes; Tabl
    839 of 7356 patients (11.4%; 3.7 events per 100 person-years) in the exenatide group and in 905 of 7396 patients (12.2%; 4.0 events per 100 person-years) (hazard ratio, 0.91; 95% CI, 0.83 to 1.00)
  • Cardiovascular death · Table 1
    Death from cardiovascular causes 340 (4.6) 1.4 383 (5.2) 1.5 0.88 (0.76–1.02)
  • All-cause death · Table 1
    Death from any cause 507 (6.9) 2.0 584 (7.9) 2.3 0.86 (0.77–0.97)
  • Myocardial infarction · Table 1
    Fatal or nonfatal myocardial infarction 483 (6.6) 2.1 493 (6.7) 2.1 0.97 (0.85–1.10)
  • Stroke · Table 1
    Fatal or nonfatal stroke 187 (2.5) 0.8 218 (2.9) 0.9 0.85 (0.70–1.03)
  • Hospitalisation for heart failure · Table 1
    Hospitalization for heart failure 219 (3.0) 0.9 231 (3.1) 1.0 0.94 (0.78–1.13)
  • Coronary revascularisation · Results, Additional Efficacy Outcomes paragraph
    The rate of cardiovascular or peripheral revascularization procedures was similar in the two groups (hazard ratio, 0.94; 95% CI, 0.85 to 1.05)

Registered trials (1)

From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.

TrialIndicationPhaseStatusStart → primary completionnResultRegistry
EXSCEL
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
CV outcomesPhase 3completed2010-06 → 2017-0414752MACE HR 0.91 (0.83–1.00): non-inferior, superiority not shownNCT01144338

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: Exenatide. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/exenatide/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.